Search
Remibrutinib
go.drugbank.com/drugs/DB16852ApprovedInvestigational[A274501, L54101] Remibrutinib has also been investigated in other inflammatory conditions,[A274511] such as autoimmune encephalomyelitis [A274501] and Sjögren's syndrome.[A274521] … The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria.
DL-dimyristoylphosphatidylglycerol
go.drugbank.com/drugs/DB11284ApprovedDL-dimyristoylphosphatidylglycerol is a phospholipid used in commercially available pharmaceutical preparations to solubilize drugs for injection.
Mometasone
go.drugbank.com/drugs/DB00764ApprovedInvestigationalMometasone is a corticosteroid not currently used in medical products. Mometasone furoate however, is still in use.
Dimetindene
go.drugbank.com/drugs/DB08801ApprovedInvestigationalDimetindene (Fenistil) is an antihistamine/anticholinergic used orally and locally as an antipruritic.
Limaprost
go.drugbank.com/drugs/DB09211InvestigationalLimaprost (as Limaprost alfadex; CAS number 88852-12-4) is an oral prostaglandin E1 analog. … It was approved for the treatment of ischemic symptoms such as skin ulcer, pain and coldness accompanying thromboangiitis obliterans in 1988; and for the treatment of subjective symptoms such as pain and
Leucine
go.drugbank.com/drugs/DB00149ApprovedInvestigationalNutraceuticalAn essential branched-chain amino acid important for hemoglobin formation.
Mixtures: LEVAMIN PAD, EAS ORAL 100 TABLETIsoleucine
go.drugbank.com/drugs/DB00167ApprovedInvestigationalNutraceuticalAn essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of leucine. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels.
Mixtures: LEVAMIN PAD, EAS ORAL 100 TABLETDermatophagoides farinae
go.drugbank.com/drugs/DB10400ApprovedInvestigationalThis combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for dust mite allergies.
Anidulafungin
go.drugbank.com/drugs/DB00362ApprovedAnidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. … There is preliminary evidence that it has a similar safety profile to caspofungin.
Nadroparin
go.drugbank.com/drugs/DB08813ApprovedInvestigationalWithdrawnIt is derived from porcine sources and has a mean molecular size of 5000 daltons.